1,000+ Opportunities
Find the right grant
Search federal, foundation, and corporate grants with AI — or browse by agency, topic, and state.
This listing may be outdated. Verify details at the official source before applying.
Find similar grantsHEAL Initiative: Development of Therapies and Technologies Directed at Enhanced Pain Management (R41/R42 Clinical Trial Not Allowed) is sponsored by National Institutes of Health (NIH). This opportunity supports mission-aligned projects and measurable outcomes.
Get a weekly digest of new grants like this
A free weekly digest of new foundation and federal funding opportunities as they're added to Granted. Unsubscribe anytime.
Or search similar grants →Extracted from the official opportunity page/RFP to help you evaluate fit faster.
A **. gov** website belongs to an official government organization in the United States.
* How to Apply for Grants * **Applicant Resources** * Adobe Software Compatibility * Submitting UTF-8 Special Characters * Encountering Error Messages * Grantor Standard Language * Submitting UTF-8 Special Characters * **Applicant System-To-System** * Reference Implementation * **Grantor System-To-System** * Reference Implementation * SF-424 Individual Family * SF-424 Mandatory Family * SF-424 Short Organization Family * Post-Award Reporting Forms * Country and State Lists Updates * **Manage Subscriptions** * Program Management Office * Grants.
gov Maintenance Calendar HEAL Initiative: Development of Therapies and Technologies Directed at Enhanced Pain Management (R41/R42 Clinical Trial Not Allowed) Department of Health and Human Services National Institutes of Health Document Type:Grants Notice Funding Opportunity Number:RFA-NS-23-007 Funding Opportunity Title:HEAL Initiative: Development of Therapies and Technologies Directed at Enhanced Pain Management (R41/R42 Clinical Trial Not Allowed) Opportunity Category:Discretionary Opportunity Category Explanation: Funding Instrument Type:Grant Category of Funding Activity:Education Income Security and Social Services Expected Number of Awards: Assistance Listings:93.
213 -- Research and Training in Complementary and Integrative Health 93. 233 -- National Center on Sleep Disorders Research 93. 242 -- Mental Health Research Grants 93.
273 -- Alcohol Research Programs 93. 350 -- National Center for Advancing Translational Sciences 93. 351 -- Research Infrastructure Programs 93.
393 -- Cancer Cause and Prevention Research 93. 395 -- Cancer Treatment Research 93. 396 -- Cancer Biology Research 93.
837 -- Cardiovascular Diseases Research 93. 838 -- Lung Diseases Research 93. 839 -- Blood Diseases and Resources Research 93.
840 -- Translation and Implementation Science Research for Heart, Lung, Blood Diseases, and Sleep Disorders 93. 846 -- Arthritis, Musculoskeletal and Skin Diseases Research 93. 853 -- Extramural Research Programs in the Neurosciences and Neurological Disorders 93.
859 -- Biomedical Research and Research Training 93.
865 -- Child Health and Human Development Extramural Research Cost Sharing or Matching Requirement:No Last Updated Date:Sep 15, 2022 Original Closing Date for Applications:Apr 04, 2025 Current Closing Date for Applications:Apr 04, 2025 Archive Date:May 10, 2025 Estimated Total Program Funding: Eligible Applicants:Small businesses Additional Information on Eligibility:Other Eligible Applicants include the following: Non-domestic (non-U.S.) Entities (Foreign Institutions) are not eligible to apply.
Non-domestic (non-U.S.) components of U.S. Organizations are not eligible to apply.
Foreign components, as defined in the NIH Grants Policy Statement, may be allowe ## Additional Information Agency Name:National Institutes of Health Description:The purpose of this Funding Opportunity Announcement (FOA) aims to speed scientific solutions to stem the national opioid public health crisis by supporting the development of therapies and technologies directed at enhanced pain management through the Small Business Technology Transfer (STTR) program.
This FOA is focused on applications directed at improving pain treatment, including the development of new non-addictive medications and devices and objective pain measurement. In addition, NIH is interested in new screening tools and models focused specifically on pain and development of pain therapies. Link to Additional Information:https://grants.
nih. gov/grants/guide/rfa-files/RFA-NS-23-007. html Grantor Contact Information:If you have difficulty accessing the full announcement electronically, please contact: See Section VII.
Agency Contacts within the full opportunity announcement for all other inquires. #### Health & Human Services * Frequently Asked Questions ## Your session will expire in 3 minutes. To continue working, click on the "OK" button below.
This is being done to protect your privacy. Unsaved changes will be lost.
According to the current listing, eligibility includes: Small businesses are typically eligible for STTR programs. Specific details on eligibility for this R41/R42 mechanism would be found in the full FOA. Confirm the full requirements in the official notice before applying.
HEAL Initiative: Development of Therapies and Technologies Directed at Enhanced Pain Management (R41/R42 Clinical Trial Not Allowed) is funded by National Institutes of Health (NIH). Verify program details on the funder's official page before applying.
Start from the official opportunity page linked in this listing — it carries the sponsor's submission instructions.
PA-27-037 consolidates the Predoctoral to Postdoctoral Transition Award into a single parent announcement across 20 NIH components, with the next deadline December 8, 2026. The eligibility gate is not the science — it is a mandatory change of institution and mentor between the F99 and K00 phases.
Read articleA draft executive order would have put OMB Director Russell Vought on a commission with final say over NIH awards after peer review. Sen. Collins killed it by pointing at a provision Congress already passed. Here is what the episode teaches applicants about the December 11 cliff.
Read articlePA-27-034, PA-27-035 and PA-27-036 replace the institute-specific R25 announcements that research education programs have been built around for a decade. NCI, NIDA and NIGMS have already expired theirs early. Here is what the consolidation actually changes: an 8% indirect cost ceiling, a US-citizens-and-permanent-residents participant rule, a cooperative agreement variant that only exists on one of the three, and no clinical-trial-allowed companion anywhere.
Read article